Full-Time

SOP & Training Specialist

Posted on 9/25/2025

Deadline 10/9/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Dorking, UK + 2 more

More locations: Canterbury, UK | High Wycombe, UK

Hybrid

Hybrid work arrangement; requires some in-office presence.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Customer Service
Requirements
  • Minimum of a Bachelor’s degree or equivalent
  • Demonstrated strong technical or digital skills in use of digital systems and new software
  • Experience with design and documentation of pharmaceutical business processes (safety, regulatory, medical and/or clinical), or equivalent, such as experience of writing communications or training materials, intended for customers, or experience with process improvement projects and/or implementation of business process change management
  • Experience of completing quality control review of pharmaceutical business process documentation (safety, regulatory, medical and/or clinical), or equivalent, such as quality control review of other types of documentation, training materials, presentations, communications or reports
  • Experience of database maintenance, such as data entry, running reports and conducting data quality checks
  • History of achievement in a customer service role with demonstration of meeting customer needs and concerns
  • Organizational skills
  • Can work independently to deliver high quality work within agreed deadlines
  • Ability to manage multiple projects and adjust priorities as needed
  • Communication skills
  • Can interact at all levels within a matrix environment, globally and locally
  • Strong English communication skills (verbal, written and listening) with ability to use a variety of communication tools and techniques to explain difficult issues and work to establish consensus
  • Administrative excellence
  • Evident attention to detail
  • Ability to maintain accurate and timely records
  • Decision making and problem solving
  • Can adapt to changing situations and works well under pressure
  • Ability to make decisions based on pre-set guidelines and procedures
  • Ability to recognize issues and work within the team to resolve problems
  • Technical proficiency
  • Demonstrated technical aptitude with use of new software and digital systems
  • Demonstrated proficiency in use of MS Office Suite, including Teams
Responsibilities
  • Reviews global procedural documents familiarize with updates/changes
  • Conducts central review of local procedural documents to determine if they are in compliance with the global procedure (impact analysis)
  • Liaise with local procedural document authors to provide feedback on the central review outcome
  • Documents outcome of central review
  • Coordinates automated notifications to authors of impacted local procedural documents that periodic assessments are due
  • Completes quality review of periodic assessments and liaise with local procedural document authors to provide feedback
  • Tracks the status assessment completion to ensure implementation and compliance
  • Issues escalation notifications to local authors who are non-compliant with periodic assessment requirements
  • Performs quality control checks for global procedural documents, by following internal processes and established standards within agreed timelines, including prioritizing multiple tasks for timely completion
  • Performs quality control checks of information in the process management relational database
  • Acts as a subject matter expert for established documentation standards and internal processes for consistency and compliance within a controlled regulatory environment, including providing accurate guidance and information to global procedural document authors
  • Assist with documentation life cycle within the Global Document Management System (GDMS) and process management relational database to maintain a state of inspection readiness
  • Provides other documentation management and assistance including, but not limited to GDMS searches, metrics, technology initiatives and process improvement projects
  • Adds data/information into the process management relational database (i.e., a database that includes business process modeling and allows for management of controlled documents and associated information with an end user interface which provides the business access to internal colleagues, auditors, vendors, and regulatory authority inspectors) by collaborating with the SOP authors
  • Completes data quality checks, periodic and ad hoc reviews of the process management relational database content including follow-up on resolution of potential content discrepancies
  • Assist the following: running of departmental metrics and other reporting activities; provides advice on process enhancements and continuous improvement, assist and resolve any questions about or issues arising from the Process portal, partake in user acceptance testing of new versions of the underlying portal management software or resolution of technical issues.
Desired Qualifications
  • Tools for process design and mapping, document management, database management, publishing, communication; familiarity of the fundamentals of electronic publishing of procedural documents
  • Experience of working with a controlled documentation management system and industry standards for compliance
  • In-depth knowledge of pharmaceutical business processes (i.e., safety, regulatory, medical, clinical trials and/or enterprise quality management system) and regulations, guidelines and industry standards for compliance.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE